相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comprehensive omics studies of p53 mutants in human cancer
Lakshay Malhotra et al.
BRIEFINGS IN FUNCTIONAL GENOMICS (2023)
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib (vol 55, pg 98, 2016
Mohammad Krayem et al.
EUROPEAN JOURNAL OF CANCER (2022)
Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells
Shengliang Zhang et al.
MOLECULAR CANCER RESEARCH (2022)
p53 partial loss-of-function mutations sensitize to chemotherapy
Boris Klimovich et al.
ONCOGENE (2022)
Mutant p53: it's not all one and the same
Margaret C. Kennedy et al.
CELL DEATH AND DIFFERENTIATION (2022)
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma
Russell Moser et al.
ONCOGENE (2022)
TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19
Joe B. Harford et al.
VIRUSES-BASEL (2022)
Arsenic Trioxide Rescues Structural p53 Mutations through a Cryptic Allosteric Site
Shuo Chen et al.
CANCER CELL (2021)
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Jiahao Hu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane
Vinaya Phatak et al.
CELL DEATH & DISEASE (2021)
Mutant p53 Gain-of-Function: Role in Cancer Development, Progression, and Therapeutic Approaches
Eduardo Alvarado-Ortiz et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Rab11-FIP1/RCP Functions as a Major Signalling Hub in the Oncogenic Roles of Mutant p53 in Cancer
Yannick von Grabowiecki et al.
FRONTIERS IN ONCOLOGY (2021)
Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells
Eduardo Garcia-Garrido et al.
PHARMACEUTICS (2021)
Clinical and Immunological Effects of p53-Targeting Vaccines
Shan Zhou et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Tumor suppressor immune gene therapy to reverse immunotherapy resistance
Sunil Chada et al.
CANCER GENE THERAPY (2021)
Viral targeting of glioblastoma stem cells with patient-specific genetic and post-translational p53 deregulations
Jon Gil-Ranedo et al.
CELL REPORTS (2021)
Structural and Drug Targeting Insights on Mutant p53
Ana Sara Gomes et al.
CANCERS (2021)
p73 as a Tissue Architect
Laura Maeso-Alonso et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Naoise C. Synnott et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
Li Ren Kong et al.
NATURE COMMUNICATIONS (2020)
Cas9 activates the p53 pathway and selects for p53-inactivating mutations
Oana M. Enache et al.
NATURE GENETICS (2020)
Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
Regina Mirgayazova et al.
GENES (2020)
Gain-of-function mutant p53 in cancer progression and therapy
Cen Zhang et al.
JOURNAL OF MOLECULAR CELL BIOLOGY (2020)
Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Yan Stein et al.
CARCINOGENESIS (2020)
Targeting DNA and mutant p53 by a naphthalimide derivative, NA20, exhibits selective inhibition in gastric tumorigenesis by blocking mutant p53-EGFR signaling pathway
Guohai Zhang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Autophagy induced by SAHA affects mutant P53 degradation and cancer cell survival
Giorgia Foggetti et al.
BIOSCIENCE REPORTS (2019)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Mingli Yang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2019)
COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms
Antje Lindemann et al.
CLINICAL CANCER RESEARCH (2019)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma
Sara Gomes et al.
CANCER LETTERS (2019)
Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
Mohan R. Pradhan et al.
NUCLEIC ACIDS RESEARCH (2019)
Therapeutic effects of statins against lung adenocarcinoma via p53 mutant-mediated apoptosis
Cheng-Wei Chou et al.
SCIENTIFIC REPORTS (2019)
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
Nicola R. Hardwick et al.
CLINICAL CANCER RESEARCH (2018)
The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic
Wei-Wei Zhang et al.
HUMAN GENE THERAPY (2018)
Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9
Sergiu Chira et al.
TRENDS IN BIOTECHNOLOGY (2018)
Genomic instability in mutant p53 cancer cells upon entotic engulfment
Hannah L. Mackay et al.
NATURE COMMUNICATIONS (2018)
p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton
Sandra Fuertes-Alvarez et al.
CELL DEATH & DISEASE (2018)
p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion
Gabriela L. Santos Guasch et al.
ISCIENCE (2018)
The interplay between mutant p53 and the mevalonate pathway
Alejandro Parrales et al.
CELL DEATH AND DIFFERENTIATION (2018)
Targeting mutant p53 for efficient cancer therapy
Vladimir J. N. Bykov et al.
NATURE REVIEWS CANCER (2018)
Mechanisms of transcriptional regulation by p53
Kelly D. Sullivan et al.
CELL DEATH AND DIFFERENTIATION (2018)
Why are there hotspot mutations in the TP53 gene in human cancers?
Evan H. Baugh et al.
CELL DEATH AND DIFFERENTIATION (2018)
Mutant p53 Gain of Function and Chemoresistance: The Role of Mutant p53 in Response to Clinical Chemotherapy
Chao He et al.
CHEMOTHERAPY (2017)
Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific statin sensitivity
Frances K. Turrell et al.
GENES & DEVELOPMENT (2017)
DNA damage-induced ephrin-B2 reverse signaling promotes chemoresistance and drives EMT in colorectal carcinoma harboring mutant p53
S. K. Alam et al.
CELL DEATH AND DIFFERENTIATION (2016)
A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas
Alice Soragni et al.
CANCER CELL (2016)
APR-246 (PRIMA-1MET) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines
Christophe Deben et al.
CANCER LETTERS (2016)
Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study
Kathleen F. Pirollo et al.
MOLECULAR THERAPY (2016)
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer
Dawid Walerych et al.
NATURE CELL BIOLOGY (2016)
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Eric Tran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cancer stem cells and chemoresistance: The smartest survives the raid
Jihe Zhao
PHARMACOLOGY & THERAPEUTICS (2016)
Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides
Perry Tal et al.
ONCOTARGET (2016)
COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
Kowthar Y. Salim et al.
ONCOTARGET (2016)
p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network
Clayton B. Marshall et al.
CELL REPORTS (2016)
p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib
Mohammad Krayem et al.
EUROPEAN JOURNAL OF CANCER (2016)
TP53: an oncogene in disguise
T. Soussi et al.
CELL DEATH AND DIFFERENTIATION (2015)
Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment
E. M. Alexandrova et al.
NATURE (2015)
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
N. Mohell et al.
CELL DEATH & DISEASE (2015)
Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
Min-Che Tung et al.
ONCOTARGET (2015)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
TAp73 is essential for germ cell adhesion and maturation in testis
Lena Holembowski et al.
JOURNAL OF CELL BIOLOGY (2014)
p53 haploinsufficiency and functional abnormalities in multiple myeloma
P. J. Teoh et al.
LEUKEMIA (2014)
Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase
Wensheng Yan et al.
PLOS ONE (2014)
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity
J. Xu et al.
CELL DEATH & DISEASE (2014)
p53 family and cellular stress responses cancer
Johanna Pflaumf et al.
FRONTIERS IN ONCOLOGY (2014)
Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells
Ameya Paranjpe et al.
CARCINOGENESIS (2013)
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
Jacqueline L. Y. Chee et al.
CELL CYCLE (2013)
Chaperone-mediated autophagy degrades mutant p53
Helin Vakifahmetoglu-Norberg et al.
GENES & DEVELOPMENT (2013)
Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors
Neil Senzer et al.
MOLECULAR THERAPY (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
Control of cell cycle transcription during G1 and S phases
Cosetta Bertoli et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2013)
Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O6-methylguanine DNA-methyltransferase
Xiang Wang et al.
NEUROLOGICAL SCIENCES (2013)
Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells
Hai-Bin Zhu et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells
Yong Weon Yi et al.
ONCOTARGET (2013)
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Osama E. Rahma et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway
William A. Freed-Pastor et al.
CELL (2012)
MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function
S. Donzelli et al.
CELL DEATH AND DIFFERENTIATION (2012)
Mutant p53 cooperates with ETS2 to promote etoposide resistance
Phi M. Do et al.
GENES & DEVELOPMENT (2012)
Chaperoning of Mutant p53 Protein by Wild-type p53 Protein Causes Hypoxic Tumor Regression
Rajan Gogna et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
A Pin1/Mutant p53 Axis Promotes Aggressiveness in Breast Cancer
Javier E. Girardini et al.
CANCER CELL (2011)
SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
D. Li et al.
CELL DEATH AND DIFFERENTIATION (2011)
Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides
Celia Floquet et al.
NUCLEIC ACIDS RESEARCH (2011)
Intracellular signaling and hepatocellular carcinoma
Polina Iakova et al.
SEMINARS IN CANCER BIOLOGY (2011)
p63 in Epithelial Survival, Germ Cell Surveillance, and Neoplasia
Christopher P. Crum et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2010)
SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53
Mark Demma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
p53-based Cancer Therapy
David P. Lane et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain
Jeremy M. R. Lambert et al.
CANCER CELL (2009)
Mutant p53 Drives Invasion by Promoting Integrin Recycling
Patricia A. J. Muller et al.
CELL (2009)
A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage
Felipe Cortes Ledesma et al.
NATURE (2009)
Transcriptional Network of p63 in Human Keratinocytes
Silvia Pozzi et al.
PLOS ONE (2009)
The disruption of the protein complex mutantp53/p73 increases selectively the response of tumor cells to anticancer drugs
Silvia Di Agostino et al.
CELL CYCLE (2008)
Mutant p53 protein localized in the cytoplasm inhibits autophagy
Eugenia Morselli et al.
CELL CYCLE (2008)
ABC multidrug transporters: structure, function and role in chemoresistance
Frances J. Sharom
PHARMACOGENOMICS (2008)
Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway
J. E. Kravchenko et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Cytotoxic drug-induced, p53-mediated upregulation of caspase-8 in tumor cells
H. Ehrhardt et al.
ONCOGENE (2008)
Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer
Marion E. Couch et al.
CLINICAL CANCER RESEARCH (2007)
A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin
Chunmei Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*0201+ squamous cell carcinomas of the head and neck
Daisuke Ito et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
PTC124 targets genetic disorders caused by nonsense mutations
Ellen M. Welch et al.
NATURE (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
Conflicting roles for p63 in skin development and carcinogenesis
Maranke I. Koster et al.
CELL CYCLE (2007)
Clinical trials with oncolytic adenovirus in China
Wang Yu et al.
CURRENT CANCER DRUG TARGETS (2007)
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P. Martins et al.
CELL (2006)
P53 promotes adenoviral replication and increases late viral gene expression
JA Royds et al.
ONCOGENE (2006)
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
M Olivier et al.
CLINICAL CANCER RESEARCH (2006)
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
SJ Antonia et al.
CLINICAL CANCER RESEARCH (2006)
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
VJN Bykov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors
MV Blagosklonny et al.
CANCER RESEARCH (2005)
Immunization with mutant p53- and K-ras-derived peptides in cancer patients:: Immune response and clinical outcome
DP Carbone et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy
CC O'Shea et al.
CANCER CELL (2005)
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
VJN Bykov et al.
ONCOGENE (2005)
The p53 pathway: positive and negative feedback loops
SL Harris et al.
ONCOGENE (2005)
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes
A Willis et al.
ONCOGENE (2004)
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
GA Lang et al.
CELL (2004)
P53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage
JM Espinosa et al.
MOLECULAR CELL (2003)
Replication of an E1B 55-kilodalton protein-deficient adenovirus (ONYX-015) is restored by gain-of-function rather than loss-of-function p53 mutants
B Hann et al.
JOURNAL OF VIROLOGY (2003)
Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14ARF tumor suppressor genes
SJ Edwards et al.
JOURNAL OF VIROLOGY (2002)
Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man
J Kuball et al.
GENE THERAPY (2002)
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage
ER Flores et al.
NATURE (2002)
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
TM Rippin et al.
ONCOGENE (2002)
A peptide that binds and stabilizes p53 core domain:: Chaperone strategy for rescue of oncogenic mutants
A Friedler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization
YH Peng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1
J Sampath et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
分享论文
